Board of Directors
Dr. Patrick Soon-Shiong
Dr. Patrick Soon-Shiong is a physician, surgeon and scientist, has pioneered novel therapies for both diabetes and cancer, published over 100 scientific papers, and has over 95 issued patents on groundbreaking advancements spanning myriad fields. He performed the world’s first encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to man islet cell transplant in diabetic patients. He invented and developed Abraxane, the nation’s first FDA-approved protein nanoparticle albumin-bound delivery technology for the treatment of cancer. Abraxane was approved by the FDA for metastatic breast cancer in 2005, lung cancer in 2012, and pancreatic cancer in 2013. Abraxane is now approved in many countries across the globe with sales of approximately $1.0 billion. From 1997 to 2010, Dr. Soon-Shiong served as founder, Chairman and Chief Executive Officer of two global pharmaceutical companies, American Pharmaceutical Partners (sold to Fresenius SE for aggregate consideration of up to $5.6 billion in 2008) and Abraxis BioScience (sold to Celgene Corporation for aggregate consideration of up to $3.6 billion in 2010). He serves as Chairman and Chief Executive Officer of NantKwest, a publicly-traded pioneering clinical-stage immunotherapy company and affiliate of NantHealth. Dr. Soon-Shiong also serves as Chairman of the Chan Soon-Shiong Family Foundation and Chairman and Chief Executive Officer of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He is an Adjunct Professor of Surgery at the University of California, Los Angeles, or UCLA, a visiting Professor at the Imperial College of London, the Executive Director of the UCLA Wireless Health Institute, a board member of the California Telehealth Network, and global director for Cancer Services and Bioinformatics at Providence Health. Dr. Soon-Shiong holds a degree in medicine from the University of the Witwatersrand and a M.Sc. in science from the University of British Columbia. He is a board certified surgeon and a fellow of the American College of Surgeons and of the Royal College of Physicians and Surgeons of Canada.
Dr. Frank R. Jones
Dr. Jones, a founder of Etubics Corporation, is a seasoned bio-tech entrepreneur and scientist. As the founder of Etubics, Dr. Jones has served as the Company’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer since its inception. He is the Principle Investigator on many of the company’s National Institute of Health grants and contracts, which total over $20 million. He also designs and directs the clinical programs for the Company and led the “first in man” clinical trial using the Company’s Adenovirus vector platform. From 1981 to 1996, Dr. Jones served as Founding Chairman and Chief Executive Officer of the publicly traded medical device company, IMRÉ CORPORATION (now Cypress Biosciences), which focused on immunoadsorption treatments for various human diseases. From 1996 to 1998, Dr. Jones was Chairman and Chief Executive Officer of Scius Corporation, a private computer technology company which developed applications to manage and operate stirred tank manufacturing products. From 1998 to 2003 he consulted to the biotechnology industry and was the Managing Partner of Haidas Ranches, LLC a family-owned land development company. From 1983 until 1986, Dr. Jones was Director of the Immune Response Program of the Pacific Northwest Research Foundation in Seattle. He was a Researcher in the Department of Complement and Effector Biology at Memorial Sloan Kettering Cancer Center (“MSKCC”) in New York City from 1980 to 1981 and was a Research Associate in the Laboratory of Veterinary Oncology at MSKCC from 1981 to 1983. Dr. Jones is member of the American Society of Clinical Oncology, American Association for Cancer Research and the Society for Immunotherapy of Cancer. He holds a Ph.D. degree from the University of Washington in Biological Structure/Cellular Immunology. He has 12 patents to his name and has published over 50 peer reviewed scientific papers. He has presented various business and scientific presentations on a national and international basis.
Mr. Charles Kim
Mr. Charles Kim, serves as Executive Vice President and Chief Legal Officer of NantWorks, LLC, which he joined in 2011. In this capacity, he also serves as General Counsel for NantWorks’ portfolio companies, including NantHealth (Nasdaq: NH) and NantKwest (Nasdaq: NK). In these roles, he leads the company’s legal department and is responsible for a broad range of legal areas for both the company and its portfolio companies, including general corporate matters, mergers and acquisitions, licensing, intellectual property and litigation. As the chief legal officer, Mr. Kim also functions as the company’s chief compliance officer, overseeing the company’s corporate compliance program to promote ethical business conduct throughout the organization. He orchestrated the merger of Etubics Corporation and NantCell in January 2016.
Prior to NantWorks, Mr. Kim served as Senior Vice President and General Counsel of Abraxis BioScience, a publicly traded biotechnology company that he joined in September 2006. While at Abraxis BioScience, he spearheaded the separation of Abraxis BioScience and APP Pharmaceuticals in November 2007, was instrumental in the subsequent sale of APP Pharmaceuticals to Fresenius in September 2008 and orchestrated the subsequent sale of Abraxis BioScience to Celgene Corporation in October 2010. During his tenure at Abraxis BioScience and APP Pharmaceuticals, Mr. Kim was involved in all aspects of business development activities, was responsible for SEC reporting and corporate governance and provided general corporate and transactional support, including participation in board meetings and overseeing litigation and other regulatory compliance. Prior to Abraxis BioScience, Mr. Kim was a member of the corporate department at the international law firm of Morrison & Foerster LLP, where he maintained a general corporate and securities practice. Mr. Kim earned his J.D. from Loyola Law School of Los Angeles and his B.A. in Economics from the University of California at Berkeley.